Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Tarsus Pharmaceuticals (TARS) EBITDA Margin: 2021-2025

Historic EBITDA Margin for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Sep 2025 value amounting to -10.39%.

  • Tarsus Pharmaceuticals' EBITDA Margin rose 3720.00% to -10.39% in Q3 2025 from the same period last year, while for Sep 2025 it was -22.18%, marking a year-over-year increase of 8119.00%. This contributed to the annual value of -63.06% for FY2024, which is 71542.00% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' EBITDA Margin stood at -10.39%, which was up 47.67% from -19.86% recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' EBITDA Margin registered a high of 3,849.94% during Q2 2023, and its lowest value of -4,393.79% during Q4 2021.
  • Over the past 3 years, Tarsus Pharmaceuticals' median EBITDA Margin value was -47.59% (recorded in 2024), while the average stood at 13.17%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first surged by 482,371bps in 2022, then crashed by 564,938bps in 2023.
  • Over the past 5 years, Tarsus Pharmaceuticals' EBITDA Margin (Quarterly) stood at -4,393.79% in 2021, then skyrocketed by 425,716bps to -136.63% in 2022, then tumbled by 18,377bps to -320.40% in 2023, then surged by 28,535bps to -35.06% in 2024, then skyrocketed by 3,720bps to -10.39% in 2025.
  • Its EBITDA Margin stands at -10.39% for Q3 2025, versus -19.86% for Q2 2025 and -32.19% for Q1 2025.